Orbital inflammation is a potentially blinding and disfiguring disease process that is often treated with systemic corticosteroids and immunosuppression; better treatments are needed.
that affect the orbit include Graves disease, granulomatosis with polyangiitis (GPA) (known previously as Wegener's granulomatosis), and nonspecific OID, which is also sometimes called orbital pseudotumor.
1,2 These inflammatory conditions are usually treated with relatively high doses of oral corticosteroids. Investigators [1] [2] [3] have advocated the use of corticosteroid-sparing drugs such as methotrexate for patients with OID to control the disease and spare patients the added morbidity of long-term corticosteroid use. In our experience, approximately one-third of patients fail to respond optimally to immunosuppressive therapy. Obviously, alternative forms of treatment are desirable. Rituximab (Rituxan; Genentech, Inc) is a monoclonal antibody that recognizes CD20, an antigen expressed on the surface of mature B lymphocytes. Rituximab was initially approved by the US Food and Drug Administration for the treatment of B-cell lymphomas, chronic lymphocytic leukemia, and moderate to severe rheumatoid arthritis (RA), but investigators have reported success in the treatment of multiple other autoimmune conditions, such as pemphigus vulgaris, 4 systemic lupus erythematosus, 5 and autoimmune hemolytic anemia. 6 Rituximab has been shown 7 to be noninferior to cyclophosphamide in the treatment of GPA and microscopic polyangiitis and has been approved by the US Food and Drug Administration for that indication. Because B lymphocytes are the progenitors of the plasma cells that make the autoantibodies characteristic of Graves disease, we reasoned that there was a strong rationale for use of rituximab in at least 2 forms of OID. Previous reports have demonstrated the efficacy of CD20 blockade in the treatment of thyroid orbitopathy 8, 9 and idiopathic OID. 10, 11 We conducted a randomized trial comparing 2 doses of rituximab for individuals with any form of noninfectious OID that had not been adequately controlled with oral corticosteroids and at least 1 additional systemic immunosuppressive medication.
Methods
All participants were recruited from the Uveitis Clinic of the Casey Eye Institute, Portland, Oregon, between January 1, 2007, and March 31, 2010 . Approval was given by the Oregon Health and Science University Institutional Review Board and by the US Food and Drug Administration. Primary end points of the study were the ability to taper corticosteroid therapy and achieve improvement in disease activity based on validated grading systems. Secondary end points included improvement in either the patient's or physician's global ocular health assessments and reduction in pain. The protocol permitted retreatment 24 to 48 weeks after initial infusion, with monthly safety assessment and outcome assessment at 24 and 48 weeks.
Before enrollment, all patients provided a detailed medical history and underwent complete ophthalmic examination and appropriate systemic evaluations to determine the cause of their orbital inflammation. All participants were 18 years or older and had noninfectious OID refractory to therapy with oral corticosteroids and at least 1 other immunosuppressive medication or were intolerant of such therapy. The Box lists the inclusion and exclusion criteria. Participants provided written informed consent and did not receive financial compensation.
All participants were required to have a purified protein derivative skin test, chest radiograph, and electrocardiogram within 3 months of enrollment. In addition, all participants underwent orbital magnetic resonance imaging and ophthalmic ultrasonography at enrollment and at weeks 24 and 48 for those who reached these end points in the study.
The first 5 patients received open-label 1000-mg infusions of rituximab. Five subsequent participants were randomized to receive either 500-mg or 1000-mg infusions of rituximab on days 1 and 15. Preinfusion prophylaxis consisted of 1 dose each of oral acetaminophen (1 g), oral diphenhydramine hydrochloride (50 mg, or an equivalent dose of a similar agent), and intravenous methylprednisolone (100 mg). Patients returned to the clinic every 4 weeks for measurement of safety and efficacy end points. Those who demonstrated an initial positive clinical response to rituximab measured at 24 weeks but experienced relapse subsequent to this were eligible for retreatment with 2 infusions of 1000 mg of rituximab separated by 2 weeks.
Ophthalmic Evaluation
Ophthalmic evaluation included determination of bestcorrected visual acuity with spectacle correction and pinhole on Snellen eye charts, applanation tonometry measurement of intraocular pressure, slitlamp biomicroscopy, and ophthalmoscopic fundus examination. Orbital inflammation activity was graded using a modified grading system first devised by Werner ( Table 1) , 12 comprising measurement of physical signs and symptoms, proptosis, extraocular muscle involvement, corneal involvement, and optic nerve involvement. In addition, at each visit, the physician and patient marked a point along a continuous 10-cm line to indicate disease activity for that day, from worst to best, on a visual analog scale (VAS). Participants similarly marked a VAS line to indicate the subjective intensity of their pain.
Systemic Evaluation and Laboratory Monitoring
Participants underwent a general physical examination before each infusion. Baseline laboratory tests included complete blood cell count with differential, comprehensive metabolic panel, urinalysis, serum uric acid, antineutrophil cytoplasmic antibody, erythrocyte sedimentation rate, C-reactive protein, and pregnancy testing; serologic reactions to detect hepatitis B, hepatitis C, and human immunodeficiency virus; and assays for the presence of human antichimeric antibodies, rituximab levels, and circulating CD19-and CD20-positive B-cell levels. CD19, similar to CD20, is a B-cell surface marker expressed by all B-lineage cells during development 
Outcome Variables and Definition of Composite Clinical End Point
The primary efficacy end point was defined as improvement in either of the following criteria: reduction in the dose of systemic corticosteroids or immunosuppressive therapy by at least 50% by 24 weeks, or a reduction in disease activity score by 2 or more or an overall score of 3 or less by 24 weeks, as measured by the modified Werner grading system. Secondary efficacy criteria were evaluated as follows: improved control of inflammation as evidenced by 25% improvement in both the physician's and participant's global ocular health assessment on a 10-cm VAS scale; 25% reduction in ocular pain, as assessed using the VAS; reduction in the analgesic dose for pain associated with orbital inflammation by dose and/or frequency; and improvement in Snellen visual acuity of 2 lines or more. Orbital inflammation was considered active or uncontrolled if the orbital inflammation grading score was greater than 3 at any examination or if the patient's and physician's global ocular health assessment was 5 cm or more on a 10-cm VAS. Tapering of systemic immunosuppressive therapy was attempted in participants with controlled disease. In general, prednisone therapy was tapered first unless it was medically necessary to first taper a concomitant immunosuppressive therapy owing to drug-related toxic effects. At each examination, the dose of prescribed immunosuppressive medications was recorded and patients were questioned about the development of any adverse effects. Each component of our composite clinical end point was graded dichotomously (yes or no for success).
Results
Demographic information for the participants is summarized in Table 2 . Seven of the 10 patients were women. The age range was 28 to 86 years (mean, 51; median, 49 years). Three individuals had Graves disease, 2 had GPA, and 5 had idiopathic OID. Five patients had bilateral disease. Two patients had concurrent OID and scleritis and were monitored both in this study and in a companion protocol ascertaining outcomes of rituximab treatment for scleritis. Per protocol requirement, all patients had received previous treatment with prednisone and at least 1 other immunomodulatory agent (range, 1-5; mean 2). Patient 2 was intolerant to prednisone because of poorly controlled diabetes.
The 24-week outcome measures are summarized in Table 3 . With regard to primary outcome variables, 7 of 10 patients (70%; binomial 95% CI, 34.8%-93.3%) noted improved control of orbital inflammation as graded on our orbital disease 
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Abbreviations: EOM, extraocular movement; VA, visual acuity. grading scale. Four of these people enrolled in the study while receiving oral corticosteroids, and all were able to successfully reduce the corticosteroid dose by at least 50%, with mean daily prednisone dose reduced from 17.5 mg to 6.9 mg. In addition, 1 person was able to discontinue the cyclophosphamide infusions in favor of subcutaneous methotrexate, which had previously been insufficient as a monotherapeutic agent. Another patient not receiving corticosteroids at baseline was able to discontinue use of methotrexate while receiving rituximab therapy. Seven participants were able to achieve one or both primary end points and all (including the 3 characterized as study failures) met multiple secondary outcome measures. With regard to these end points, 7 of 10 participants noted 25% or more improvement in self-assessed global health as measured on a VAS, and 8 of 10 had a similar improvement in physician-graded global health. Seven individuals noted a 25% or more reduction in pain and/or analgesic use during the course of the study. Three of the first 4 patients who received rituximab infusions developed exacerbations of ocular or systemic inflammatory disease in the early (2-to 8-week) period after infusion. All exacerbations were treated successfully with oral corticosteroids, usually in the range of 40 to 60 mg, and therapy was gradually tapered during the following 1 to 2 months to their preinfusion dosage. The dosage was then tapered further per the study protocol. All 4 of these individuals went on to demonstrate a positive treatment effect by week 24. Subsequent to the 3 participants who developed exacerbations, we administered 40 to 60 mg/d of oral prednisone as pretreatment for at least 3 days before and after all patients' initial infusions, with a more judicious tapering regimen during the first month after infusions, unless there was a specific contraindication to doing so. No further peri-infusional inflammatory flares were noted.
Reduction of circulating B cells occurred immediately in all patients who received treatment and was usually sustained for the entire 48-week treatment period. The mean pretreatment percentage of circulating B lymphocytes expressing CD19 and CD20 was 12.2% (range, 2.7%-22.2%); in all patients, this was reduced to less than 1% after receiving the first of the 2 loading infusions. Three of 6 individuals who did not receive retreatment had partial recovery of B cells from 43 to 48 weeks after infusions to levels ranging from 1.4% to 3.8%, which did not appear to be correlated with recurrence of inflammatory disease. No evidence of human antichimeric antibodies formation was found in any patient. No treatmentlimiting adverse effects or laboratory abnormalities were noted, although one patient developed cellulitis 8 weeks after treatment, which was successfully treated with antibiotics. The same person also developed an esophageal abscess and thrush, which were also successfully treated. With regard to dose effects, no evidence of differential effectiveness or toxicity was found on comparison of the 3 patients who received 500 mg and 7 who received 1000 mg. Similarly, we noted no clear differential effectiveness by diagnosis, with 2 of 3 individuals with Graves disease responding to therapy, 1 of whom required retreatment, compared with 3 of 5 with idiopathic OID (1 retreatment) and 2 of 2 with GPA, both of whom received retreatment. In total, 4 patients (2 from each dosage group) who showed an initial beneficial effect at week 24 required retreatment between weeks 24 and 48.
Discussion
To our knowledge, this study is the first prospective interventional trial of rituximab in the treatment of orbital inflammation. The classic treatment for OID has been the use of highdose oral corticosteroids, 1, 13 with some authors 14, 15 advocating the addition of orbital irradiation. This therapy is often initially successful, but relapses are common because the underlying cause is not addressed. 16, 17 Corticosteroid-sparing agents have been successfully used to help reduce the effects of longterm prednisone. 3 Biologic response modifiers are becoming more commonly used in the treatment of refractory ocular inflammation and directly target the inflammatory mediators that induce and propagate ocular inflammation. 18 Previous reports have demonstrated success with tumor necrosis factor 30 More recent studies 31 have demonstrated similar efficacy to the standard 1000-mg doses, with 2 doses of 500 mg given 2 weeks apart in RA, and a recent small study 32 suggested rapid effectiveness of doses as low as 100 mg. We found no statistically significant difference in efficacy, duration of effect, B-cell depletion, or toxic effects between the 2 studied dosages, although a study of this size would be able to distinguish only a very large differential effect. Additional studies are needed to support this observation to mitigate the potential risks of toxic effects with overtreatment and increased cost without clinical benefit. Rituximab is known to be safe based on use in large cohorts of patients with rheumatic disease. A pooled case analysis of nearly 3200 patients found no significant difference in the rates of serious infections, malignancy, or death compared with those in the general RA population. 27 The drug's safety in ophthalmic disease is less well established; however, we found no treatment-limiting toxic effects with this medication that were definitely attributable to study therapy. However, 3 of our patients who received initial treatment experienced disease exacerbation within 2 to 8 weeks of the first infusion of 1000 mg of rituximab. Each responded to corticosteroid therapy. Interestingly, this acute disease flare was also seen in a previously reported pemphigus series 4 and more recently in a series of rituximab-treated patients with Graves orbitopathy. 32 We have also observed this in patients with scleritis (unpublished findings). We hypothesize, as have previous investigators, that this effect is due to rapid B-cell elimination causing cytokine release and creating a tumor lysislike effect within the affected orbit. Corticosteroid therapy successfully blunted peri-infusional flares in all subsequent patients and is now part of our standard protocol for rituximab therapy in all patients with inflammatory eye disease. The occurrence of these flares did not appear to negatively affect 24-and 48-week outcomes.
Conclusions
Rituximab appears to be safe, and it improved orbital inflammation in 7 of 10 patients, suggesting potential effectiveness in patients similar to those enrolled in this trial through at least 48 weeks of treatment. Findings from a small study with a heterogeneous population and multiple dosing arms must be interpreted cautiously. Further study is necessary to determine subsets of patients who may benefit most from rituximab therapy for OID, as well as optimal dosing and intervals for treatment.
